Data mining of the public version of the FDA Adverse Event Reporting System
- PMID: 23794943
- PMCID: PMC3689877
- DOI: 10.7150/ijms.6048
Data mining of the public version of the FDA Adverse Event Reporting System
Abstract
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses.
Keywords: Adverse Event Reporting System; FAERS; adverse event; data mining; database; empirical Bayes geometric mean; information component; pharmacoepidemiology; pharmacovigilance.; proportional reporting ratio; reporting odds ratio; signal; signal detection.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
References
-
- Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10:407–410. - PubMed
-
- Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165:1363–1369. - PubMed
-
- U.S. Food and Drug Administration (FDA) http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveil.... - PubMed
-
- MedDRA MSSO. http://www.meddramsso.com/index.asp.
-
- Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167:1752–1759. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
